Has Martin Farlow, MD received payments from drug or device companies?

Yes. Drug and device makers reported $147,869 in general payments to Martin Farlow, MD across 82 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Martin Farlow, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Martin Farlow, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Martin Farlow, MD

Neurology · Indianapolis, INNPI 1508880022

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $145,979 of the $147,869 with a category attached, or 98.7%. 11 manufacturers reported payments, led by Eli Lilly at 25.0% of the total. Reporting peaked in 2020 at $47,448 and has fallen 91.3% since, to $4,127 in 2025. Among neurology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$147,869in general payments, 2019–2025

Across 82 payments — averaging $1803.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$37K
Otsuka Pharmaceutical Development & Commercialization, Inc.$27K
Avanir Pharmaceuticals, Inc.$24K
Biogen$18K
Eisai Inc.$15K
Merz North America, Inc.$13K
plus $14K from 5 others

$4,672,017in research payments, 2019–2025

Across 590 payments — averaging $7918.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eisai Inc.$1.4M
Biogen$810K
Janssen Research & Development, LLC$643K
AbbVie$607K
Novartis$520K
Eli Lilly$363K
plus $280K from 6 others

What the payments were for

Consulting fees$145,97999%
Travel & lodging$1,1481%
Food & beverage$7431%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	10	$37,013
Otsuka Pharmaceutical Development & Commercialization, Inc.	18	$27,325
Avanir Pharmaceuticals, Inc.	12	$23,804
Biogen	11	$18,387
Eisai Inc.	16	$15,244
Merz North America, Inc.	3	$12,500
Merck	6	$8,513
Novo Nordisk	3	$3,740
Genentech, Inc.	1	$1,200
Axsome Therapeutics, Inc.	1	$119
Novartis	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

REXULTI$8,200
NONE$3,510
Leqembi$125

How this compares

$147,869 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana →

Medicare billing

Part B allowed, 2024

$26,246

Medicare patients

173

Services billed

254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Rivastigmine	142	$33,856
Memantine Hcl	312	$14,658
Donepezil Hcl	598	$8,197
Duloxetine Hcl	109	$4,114
Escitalopram Oxalate	260	$2,771
Mirtazapine	95	$2,017
Quetiapine Fumarate	121	$1,545
Carbidopa-LevodopaCarbidopa/Levodopa	29	$1,228
Solifenacin Succinate	16	$1,055
Olanzapine	29	$637
Bupropion XlBupropion Hcl	17	$518
Bupropion Hcl SrBupropion Hcl	23	$480
Levetiracetam	21	$463
Sertraline Hcl	28	$374
Gabapentin	33	$356

Paid to pharmacies, not to this prescriber.

Other neurology in Indianapolis

Cassandra CurtisIndianapolis$181K
Eric SiemersIndianapolis$101K
Liana ApostolovaIndianapolis$95K
Jared BroschIndianapolis$68K
Kaustubh LimayeIndianapolis$44K
Michael SermersheimIndianapolis$32K
Cynthia McGarveyIndianapolis$27K
David GlanderIndianapolis$25K
Leo DambrosioIndianapolis$25K
Kuimil MohanIndianapolis$23K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →